Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
917 DKK | +0.30% | +2.13% | +30.96% |
08:41am | CAC 40: no major upheaval after BoJ meeting | CF |
Mar. 18 | Novo Nordisk Foundation to Boost Grants Outside Denmark | MT |
Sales 2024 * | 287B 41.8B | Sales 2025 * | 345B 50.24B | Capitalization | 4,079B 594B |
---|---|---|---|---|---|
Net income 2024 * | 103B 15.05B | Net income 2025 * | 124B 18.08B | EV / Sales 2024 * | 14.3 x |
Net Debt 2024 * | 25.84B 3.76B | Net Debt 2025 * | 2.2B 321M | EV / Sales 2025 * | 11.8 x |
P/E ratio 2024 * |
39.5
x | P/E ratio 2025 * |
32.4
x | Employees | 63,845 |
Yield 2024 * |
1.29% | Yield 2025 * |
1.55% | Free-Float | 70.79% |
Latest transcript on Novo Nordisk A/S
1 day | +1.13% | ||
1 week | +2.13% | ||
Current month | +11.53% | ||
1 month | +7.44% | ||
3 months | +34.82% | ||
6 months | +40.56% | ||
Current year | +30.96% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 90-12-31 | |
Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
21.31% | 196 M€ | +10.20% | ||
10.45% | 5 M€ | +11.88% | ||
5.40% | 18 M€ | +5.16% | - | |
4.67% | 88 M€ | +10.37% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 914.2 | +1.13% | 2 038 452 |
24-03-15 | 904 | -2.22% | 5,984,147 |
24-03-14 | 924.5 | +2.10% | 2,484,956 |
24-03-13 | 905.5 | -1.02% | 2,335,821 |
24-03-12 | 914.8 | +2.20% | 2,504,551 |
Delayed Quote Nasdaq Copenhagen, March 18, 2024 at 11:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.96% | 595B | |
+30.83% | 687B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.78% | 211B | |
-6.09% | 208B | |
-2.92% | 203B | |
-3.72% | 157B | |
-5.94% | 145B |